Skip to main content
Journals

Hyaluronic Acid Injection Techniques for Lip Augmentation—Comparison of Linear, Retrograde, and Microdeposit Approaches: A Systematic Review

Aesthetic Surgery Journal Open Forum
Aesthetic Surgery Journal Open Forum

Author: Victor Rene Miranda Cerna, MD

Abstract: Hyaluronic acid (HA) is widely used for lip augmentation; however, the safety and performance of injection techniques and instruments (needle vs cannula) remain unclear. The aim of this study was to evaluate the safety of HA injection techniques for lip augmentation and to assess patient satisfaction, injected volume, and associations with technique, instrument, and HA product. A systematic review was conducted accordance with PRISMA 2020 and registered in PROSPERO (CRD420251123328). PubMed/MEDLINE, Embase, Cochrane Library, LILACS, SciELO, and Scopus were searched from January 1, 2010, to August 16, 2025, for studies involving adults undergoing HA lip augmentation. Eligible designs included randomized and nonrandomized clinical trials, cohort studies, and systematic reviews. The primary outcome was safety, defined by type and timing of complications. Secondary outcomes included patient satisfaction, injected volume, and associations with technique, instrument, and HA product. Risk of bias was assessed using RoB 2 and ROBINS-I, and findings were synthesized narratively. Sixteen studies including 3692 patients were analyzed. Most protocols used 1 to 2 mL per session, commonly employing linear retrograde techniques with serial puncture, fan patterns, or microdeposits. Adverse events were mild and transient, including edema, ecchymosis, tenderness, and nodularity, with no reported cases of vascular occlusion or vision-threatening events. Needle-only and combined needle plus cannula approaches showed comparable safety profiles. Patient satisfaction was high in most patients. HA lip augmentation appears effective and generally safe when performed by experienced injectors. Current evidence does not support a single superior technique, instrument, or HA formulation. Standardized studies are needed to define best-practice protocols.

JOURNAL ARTICLE

Related Articles

AbobotulinumtoxinA (aboBoNT-A; Dysport®) is approved in China for treating glabellar lines (GLs) with fast onset of action (median: 2 days) and effectiveness up to 6 months (Chinese pivotal trial data), but real-world data remain limited. This study’s primary objective is to assess patient satisfaction following 3 cycles of aboBoNT-A treatment for moderate-to-severe GLs in a real-world setting.
Hyaluronidase is often described as “dissolving” dermal filler, but this term oversimplifies how the enzyme actually interacts with long-standing filler within living tissue. This article explains why hyaluronidase more accurately modifies a complex filler–tissue system rather than completely eliminating filler, and why clearer terminology improves patient understanding, clinical decision-making, and ethical practice in aesthetic medicine.
Botulinum neurotoxin A (BoNT-A) is widely used clinically; yet, its temporary effects require repeated injections that increase cost and inconvenience. There is limited rigorous evidence to support claims that repeated BoNT-A use alters efficacy. Unlike peripheral nerve transection, which causes irreversible denervation after 12 to 24 months, the long-term physiological effects of BoNT-A chemodenervation remain unclear.